BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 14, 2006
View Archived Issues
Volociximab well tolerated in phase II trials
Read More
Phase I studies of ADH-1 in patients with solid tumors reported
Read More
Denosumab progresses to phase II investigation in cancer patients
Read More
Pfizer reports on a novel COX-2 inhibitor with peripheral selectivity
Read More
New phase IIa results for allergy vaccine CYT003-QbG10
Read More
Pfizer responds to negative Lipitor publicity
Read More
Phase II/III results for MN-305 in GAD
Read More
Update on study of Aptivus in treatment-naive HIV patients
Read More
Novozymes to acquire Delta Biotechnology
Read More
Sunesis earns preclinical milestone payment in BACE collaboration with Merck
Read More
Avigen to study AV-411 for neuropathic pain
Read More
IND approval for study of Tectin
Read More
MB-06322, a fructose-1,6-bisphosphatase inhibitor, effective in rat models of type 2 diabetes
Read More
Novel alpha7 nAChR agonist for cognitive deficits in schizophrenia described by Pfizer
Read More
Bcl-2 antagonists show promise in chronic lymphocytic leukemia
Read More
Administration of MVA-5T4 feasible in renal cell carcinoma, colorectal cancer
Read More
Amendments approved for TRIUMPH study of treprostinil
Read More
NDA submission planned for VQD-001 for leishmaniasis
Read More
Metaglidasen begins phase II/III study in type 2 diabetes
Read More
Soliris meets endpoints with statistical significance in second phase III PNH study
Read More
New agents for treating diabetes and other endocrine disorders disclosed in recent patents
Read More
Novel antiinfective drugs disclosed in recent patent literature
Read More
Recent patents disclose new anti-HCV compounds
Read More
Wellbutrin XL approved for prevention of seasonal major depressive episodes
Read More
Panitumumab granted priority review for metastatic colorectal cancer
Read More
Priority review granted for Saforis in oral mucositis
Read More
Pharmion's filing for i.v. dosing of Vidaza accepted for filing
Read More
Glycosphingolipid synthesis inhibitor, Genz-123346, improves glucose control and insulin sensitivity
Read More
SB-509 is well tolerated in phase I clinical trials
Read More
N-Gene presents positive phase II results for BGP-15, its new insulin sensitizer
Read More